Dr. Shilpa Dugar
Consultant – Paediatric Hepatology
Paediatrics (Ped)
Max Super Speciality Hospital, Saket
Share Doctor Profile
Select Hospital
About Dr. Shilpa Dugar
- 4 yrs of exclusive practice in paediatric hepatology and live transplant
- MBBS
- MD PAEDIATRICS ( Distinction)
- ISPGHAN Clinical Fellowship in Paediatric Gastroenterology
- KEM PUNESenior Clinical Fellow: Paediatric Hepatology & Liver Transplant
- KINGS COLLEGE & HOSPITAL, Denmark Hill, LONDON (United Kingdon)
- General Medical Council : 7660478
- Maharashtra Medical Council : 2012/03/0478
- PaediatricLiver transplant : pre-transplant optimization and post-transplant management (post-transplant infections, acute and chronic rejection)
- PTLD : Diagnosis and management
- Liver transplant in metabolic liver conditions like urea cycle disorders like OTC deficiencies and propionic acidemias
- Small bowel transplants and its management.
Research work experience as SUB INSPECTOR in three multinational multicenter trials as mentioned below:
*Study 1 :This is a multicenter, multinational, open-label study of to evaluate the long-term safety, tolerability, and efficacy of VTS-270 (2-hydroxypropyl- β-cyclodextrin) in participants transitioning from Study VTS301 in participants with Neurologic Manifestations of Niemann-Pick Type C1 Disease.
*Study 2 : A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease (HGT-GCB-068).
*Study 3: Multicenter, double-blinded, Randomized, Placebo-controlled trial of Arimoclomol in patients diagnosed with Gaucher Disease Type 1 or 3.
Further Details about each study available on clinicaltrials.gov.
PUBLICATIONS:
1. Tassos G, Acharya S, Shilpa Dugar. Novel compound heterozygous STN1 variants are associated with Coats Plus syndrome. Molecular Genetics & Genomic Medicine Journal. Article ID : MGG31708,Article DOI: 10.1002/mgg3.1708. Internal Article ID: 17085404.
2. Shilpa Dugar, C. S. Rajput, Sudha Bhave .Clinicoetiological co-relation of seizure disorder in childhood diseases: International Journal of Advanced Research (2015), Volume 3, Issue 12, 1366 –1367
*Study 1 :This is a multicenter, multinational, open-label study of to evaluate the long-term safety, tolerability, and efficacy of VTS-270 (2-hydroxypropyl- β-cyclodextrin) in participants transitioning from Study VTS301 in participants with Neurologic Manifestations of Niemann-Pick Type C1 Disease.
*Study 2 : A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease (HGT-GCB-068).
*Study 3: Multicenter, double-blinded, Randomized, Placebo-controlled trial of Arimoclomol in patients diagnosed with Gaucher Disease Type 1 or 3.
Further Details about each study available on clinicaltrials.gov.
PUBLICATIONS:
1. Tassos G, Acharya S, Shilpa Dugar. Novel compound heterozygous STN1 variants are associated with Coats Plus syndrome. Molecular Genetics & Genomic Medicine Journal. Article ID : MGG31708,Article DOI: 10.1002/mgg3.1708. Internal Article ID: 17085404.
2. Shilpa Dugar, C. S. Rajput, Sudha Bhave .Clinicoetiological co-relation of seizure disorder in childhood diseases: International Journal of Advanced Research (2015), Volume 3, Issue 12, 1366 –1367